LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Listă Acțiuni・Ardelyx Inc

Ardelyx Inc

Închisă

SectorSănătate

6.6 -2.22

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

6.57

Maxim

6.82

Indicatori cheie
By Trading Economics
Venit	-37M -38M
Vânzări	-31M 94M
EPS	-0.15
Marjă de profit	-39.805
Angajați	489
EBITDA	-42M -32M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+144.84% upside

Dividende
By Dow Jones
Următoarele câștiguri	3 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	334M 1.8B
Deschiderea anterioară	8.82
Închiderea anterioară	6.6

Sentimentul știrilor

By Acuity

26%

74%

60 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

3.62 / 3.95 Suport & Rezistență

Ardelyx Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 mai 2026, 23:47 UTC

Market Talk

Gold Falls on Renewed Inflation Concerns -- Market Talk

10 mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10 mai 2026, 23:38 UTC

Market Talk

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10 mai 2026, 23:14 UTC

Market Talk

Australia's Political Map Continues to Be Redrawn -- Market Talk

10 mai 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Elevra Lithium: Expects Deal to Close in 1Q FY27

10 mai 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10 mai 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10 mai 2026, 10:21 UTC

Câștiguri

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9 mai 2026, 06:05 UTC

Câștiguri

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8 mai 2026, 23:55 UTC

Câștiguri

Review & Preview: Still Going Strong -- Barrons.com

8 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 mai 2026, 20:49 UTC

Câștiguri

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mai 2026, 20:25 UTC

Câștiguri

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mai 2026, 19:43 UTC

Câștiguri

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mai 2026, 19:43 UTC

Câștiguri

Cencosud 1Q Net $115M

8 mai 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mai 2026, 19:18 UTC

Câștiguri

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mai 2026, 19:16 UTC

Câștiguri

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mai 2026, 19:08 UTC

Câștiguri

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mai 2026, 19:05 UTC

Câștiguri

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mai 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mai 2026, 18:51 UTC

Câștiguri

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mai 2026, 18:49 UTC

Câștiguri

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mai 2026, 18:41 UTC

Câștiguri

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mai 2026, 17:14 UTC

Câștiguri

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mai 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparație

Modificare preț

Ardelyx Inc Așteptări

Obiectiv de preț

By TipRanks

144.84% sus

Prognoză pe 12 luni

Medie 16.6 USD 144.84%

Maxim 19 USD

Minim 13 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArdelyx Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Ardelyx Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

3.62 / 3.95Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bearish.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

60 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.